About this trial
Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue disease (CTD) is still not well defined, particularly regarding its prevalence, incidence and the management of a broad spectrum of disease presentations.
Major challenges include the identification of patients with progressive disease, the appropriate time point of therapeutic intervention and the underlying driver of disease (inflammatory or pro-fibrotic stimulus or both?).
To address these issues in Western Austria, a progressive registry of patients with CTD exploring routine clinical and pathophysiological characteristics of ILD and PH will be conducted. This multidisciplinary, prospective and observational registry aims to collect comprehensive clinical data on incidence, prevalence and course of disease regarding all PH and ILD presentations in a real-world setting.
Eligibility criteria
Qualifiers
The inclusion criteria are adult patients (≥18 years) diagnosed with CTD with signed informed consent.
Disqualifiers
Exclusion criteria are patients with a serious co-morbidity interfering with the course of interstitial lung disease or pulmonary hypertension.
Trial design
Treatments tested in this trial
- Pulmonary function test
- Imaging
- Blood sampling
Treatment groups
Sponsors and collaborators
Medical University Innsbruck
Lead sponsor
Boehringer Ingelheim
Collaborator